Small CDMO

Neuland Laboratories Ltd.

NEULANDLAB

Market Cap
₹24,086 Cr.
P/E
66.17

Neuland Laboratories Ltd.

  • Neuland Laboratories
  • Gufic Biosciences
  • Alivus Life Sciences
  • TJI Pharma - Small Cap

FAQs on Neuland Laboratories Ltd. Shareprice

Neuland Laboratories has given better returns compared to its competitors.
Neuland Laboratories has grown at ~96.59% over the last 4yrs while peers have grown at a median rate of 28.0%

Yes, Neuland Laboratories is expensive.
Latest PE of Neuland Laboratories is 66.17, while 3 year average PE is 45.49.
Also latest EV/EBITDA of Neuland Laboratories is 41.65 while 3yr average is 30.16.

View FAQ's On Business

Growth Table

  • Neuland Laboratories Ltd.
  • Gufic Biosciences
  • Alivus Life Sciences

Balance Sheet

  • Neuland Laboratories Ltd.
  • Gufic Biosciences
  • Alivus Life Sciences

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Neuland Laboratories Ltd.
  • Gufic Biosciences
  • Alivus Life Sciences

Cash Flow

  • Neuland Laboratories Ltd.
  • Gufic Biosciences
  • Alivus Life Sciences

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Neuland Laboratories Ltd.
  • Gufic Biosciences
  • Alivus Life Sciences

Quarterly Results

  • Neuland Laboratories Ltd.
  • Gufic Biosciences
  • Alivus Life Sciences

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Neuland Laboratories Ltd. Financials

Balance sheet of Neuland Laboratories is strong.
It shouldn't have solvency or liquidity issues.

The net debt of Neuland Laboratories is decreasing.
Latest net debt of Neuland Laboratories is -₹513.25 Crs as of Mar-26.
This is less than Mar-25 when it was -₹381.59 Crs.

The profit is oscillating.
The profit of Neuland Laboratories is ₹364 Crs for Mar 2026, ₹260 Crs for Mar 2025 and ₹300 Crs for Mar 2024

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Neuland Laboratories latest dividend payout ratio is 11.98% and 3yr average dividend payout ratio is 7.96%

Companies resources are allocated to majorly unproductive assets like Accounts Receivable

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech